

Global Remicade (Infliximab) Monoclonal Antibody Supply, Demand and Key Producers, 2023-2029

<https://marketpublishers.com/r/G17A07E3B292EN.html>

Date: June 2023

Pages: 81

Price: US\$ 4,480.00 (Single User License)

ID: G17A07E3B292EN

Abstracts

The global Remicade (Infliximab) Monoclonal Antibody market size is expected to reach \$ 3781.3 million by 2029, rising at a market growth of 5.4% CAGR during the forecast period (2023-2029).

The Remicade (Infliximab) monoclonal antibody market is driven by several factors. One of the primary drivers is the high prevalence of chronic autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, and psoriasis, which require targeted immunotherapy for effective management. Remicade, as a monoclonal antibody, has demonstrated significant efficacy in treating these conditions by specifically targeting and inhibiting tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation. Additionally, the increasing adoption of biologic therapies, including monoclonal antibodies, in clinical practice has fueled the demand for Remicade. The proven clinical efficacy, long-term safety profile, and established therapeutic outcomes have contributed to its market growth. Moreover, the expanding patient pool, coupled with the rising awareness and diagnosis rates of autoimmune diseases, has created a greater demand for targeted biologic treatments like Remicade. Furthermore, the presence of robust research and development activities aimed at developing novel monoclonal antibodies and exploring new indications for Remicade continues to drive market growth. Overall, the Remicade monoclonal antibody market is driven by the high prevalence of autoimmune diseases, increasing adoption of biologic therapies, established clinical efficacy, expanding patient pool, and ongoing research and development efforts.

Infliximab is a monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Avsola, Flixabi, Inflectra, Remicade,

Renflexis.

This report studies the global Remicade (Infliximab) Monoclonal Antibody production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Remicade (Infliximab) Monoclonal Antibody, and provides market size (US\$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Remicade (Infliximab) Monoclonal Antibody that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Remicade (Infliximab) Monoclonal Antibody total production and demand, 2018-2029, (K Units)

Global Remicade (Infliximab) Monoclonal Antibody total production value, 2018-2029, (USD Million)

Global Remicade (Infliximab) Monoclonal Antibody production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Remicade (Infliximab) Monoclonal Antibody consumption by region & country, CAGR, 2018-2029 & (K Units)

U.S. VS China: Remicade (Infliximab) Monoclonal Antibody domestic production, consumption, key domestic manufacturers and share

Global Remicade (Infliximab) Monoclonal Antibody production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)

Global Remicade (Infliximab) Monoclonal Antibody production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Remicade (Infliximab) Monoclonal Antibody production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)

This reports profiles key players in the global Remicade (Infliximab) Monoclonal Antibody market based on the following parameters – company overview, production,

value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include J & J, Pfizer, Organon and Amgen, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Remicade (Infliximab) Monoclonal Antibody market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), volume (production, consumption) & (K Units) and average price (US\$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Remicade (Infliximab) Monoclonal Antibody Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Remicade (Infliximab) Monoclonal Antibody Market, Segmentation by Type

Brand

Biosimilar

Global Remicade (Infliximab) Monoclonal Antibody Market, Segmentation by Application

Ankylosing Spondylitis

Rheumatoid Arthritis

Crohn's Disease

Other

Companies Profiled:

J & J

Pfizer

Organon

Amgen

Key Questions Answered

1. How big is the global Remicade (Infliximab) Monoclonal Antibody market?
2. What is the demand of the global Remicade (Infliximab) Monoclonal Antibody market?
3. What is the year over year growth of the global Remicade (Infliximab) Monoclonal Antibody market?
4. What is the production and production value of the global Remicade (Infliximab) Monoclonal Antibody market?

5. Who are the key producers in the global Remicade (Infliximab) Monoclonal Antibody market?

6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 Remicade (Infliximab) Monoclonal Antibody Introduction
- 1.2 World Remicade (Infliximab) Monoclonal Antibody Supply & Forecast
 - 1.2.1 World Remicade (Infliximab) Monoclonal Antibody Production Value (2018 & 2022 & 2029)
 - 1.2.2 World Remicade (Infliximab) Monoclonal Antibody Production (2018-2029)
 - 1.2.3 World Remicade (Infliximab) Monoclonal Antibody Pricing Trends (2018-2029)
- 1.3 World Remicade (Infliximab) Monoclonal Antibody Production by Region (Based on Production Site)
 - 1.3.1 World Remicade (Infliximab) Monoclonal Antibody Production Value by Region (2018-2029)
 - 1.3.2 World Remicade (Infliximab) Monoclonal Antibody Production by Region (2018-2029)
 - 1.3.3 World Remicade (Infliximab) Monoclonal Antibody Average Price by Region (2018-2029)
 - 1.3.4 North America Remicade (Infliximab) Monoclonal Antibody Production (2018-2029)
 - 1.3.5 Europe Remicade (Infliximab) Monoclonal Antibody Production (2018-2029)
 - 1.3.6 China Remicade (Infliximab) Monoclonal Antibody Production (2018-2029)
 - 1.3.7 Japan Remicade (Infliximab) Monoclonal Antibody Production (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Remicade (Infliximab) Monoclonal Antibody Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Remicade (Infliximab) Monoclonal Antibody Major Market Trends
- 1.5 Influence of COVID-19 and Russia-Ukraine War
 - 1.5.1 Influence of COVID-19
 - 1.5.2 Influence of Russia-Ukraine War

2 DEMAND SUMMARY

- 2.1 World Remicade (Infliximab) Monoclonal Antibody Demand (2018-2029)
- 2.2 World Remicade (Infliximab) Monoclonal Antibody Consumption by Region
 - 2.2.1 World Remicade (Infliximab) Monoclonal Antibody Consumption by Region (2018-2023)
 - 2.2.2 World Remicade (Infliximab) Monoclonal Antibody Consumption Forecast by Region (2024-2029)

2.3 United States Remicade (Infliximab) Monoclonal Antibody Consumption (2018-2029)

2.4 China Remicade (Infliximab) Monoclonal Antibody Consumption (2018-2029)

2.5 Europe Remicade (Infliximab) Monoclonal Antibody Consumption (2018-2029)

2.6 Japan Remicade (Infliximab) Monoclonal Antibody Consumption (2018-2029)

2.7 South Korea Remicade (Infliximab) Monoclonal Antibody Consumption (2018-2029)

2.8 ASEAN Remicade (Infliximab) Monoclonal Antibody Consumption (2018-2029)

2.9 India Remicade (Infliximab) Monoclonal Antibody Consumption (2018-2029)

3 WORLD REMICADE (INFLIXIMAB) MONOCLONAL ANTIBODY MANUFACTURERS COMPETITIVE ANALYSIS

3.1 World Remicade (Infliximab) Monoclonal Antibody Production Value by Manufacturer (2018-2023)

3.2 World Remicade (Infliximab) Monoclonal Antibody Production by Manufacturer (2018-2023)

3.3 World Remicade (Infliximab) Monoclonal Antibody Average Price by Manufacturer (2018-2023)

3.4 Remicade (Infliximab) Monoclonal Antibody Company Evaluation Quadrant

3.5 Industry Rank and Concentration Rate (CR)

3.5.1 Global Remicade (Infliximab) Monoclonal Antibody Industry Rank of Major Manufacturers

3.5.2 Global Concentration Ratios (CR4) for Remicade (Infliximab) Monoclonal Antibody in 2022

3.5.3 Global Concentration Ratios (CR8) for Remicade (Infliximab) Monoclonal Antibody in 2022

3.6 Remicade (Infliximab) Monoclonal Antibody Market: Overall Company Footprint Analysis

3.6.1 Remicade (Infliximab) Monoclonal Antibody Market: Region Footprint

3.6.2 Remicade (Infliximab) Monoclonal Antibody Market: Company Product Type Footprint

3.6.3 Remicade (Infliximab) Monoclonal Antibody Market: Company Product Application Footprint

3.7 Competitive Environment

3.7.1 Historical Structure of the Industry

3.7.2 Barriers of Market Entry

3.7.3 Factors of Competition

3.8 New Entrant and Capacity Expansion Plans

3.9 Mergers, Acquisition, Agreements, and Collaborations

4 UNITED STATES VS CHINA VS REST OF THE WORLD

4.1 United States VS China: Remicade (Infliximab) Monoclonal Antibody Production Value Comparison

4.1.1 United States VS China: Remicade (Infliximab) Monoclonal Antibody Production Value Comparison (2018 & 2022 & 2029)

4.1.2 United States VS China: Remicade (Infliximab) Monoclonal Antibody Production Value Market Share Comparison (2018 & 2022 & 2029)

4.2 United States VS China: Remicade (Infliximab) Monoclonal Antibody Production Comparison

4.2.1 United States VS China: Remicade (Infliximab) Monoclonal Antibody Production Comparison (2018 & 2022 & 2029)

4.2.2 United States VS China: Remicade (Infliximab) Monoclonal Antibody Production Market Share Comparison (2018 & 2022 & 2029)

4.3 United States VS China: Remicade (Infliximab) Monoclonal Antibody Consumption Comparison

4.3.1 United States VS China: Remicade (Infliximab) Monoclonal Antibody Consumption Comparison (2018 & 2022 & 2029)

4.3.2 United States VS China: Remicade (Infliximab) Monoclonal Antibody Consumption Market Share Comparison (2018 & 2022 & 2029)

4.4 United States Based Remicade (Infliximab) Monoclonal Antibody Manufacturers and Market Share, 2018-2023

4.4.1 United States Based Remicade (Infliximab) Monoclonal Antibody Manufacturers, Headquarters and Production Site (States, Country)

4.4.2 United States Based Manufacturers Remicade (Infliximab) Monoclonal Antibody Production Value (2018-2023)

4.4.3 United States Based Manufacturers Remicade (Infliximab) Monoclonal Antibody Production (2018-2023)

4.5 China Based Remicade (Infliximab) Monoclonal Antibody Manufacturers and Market Share

4.5.1 China Based Remicade (Infliximab) Monoclonal Antibody Manufacturers, Headquarters and Production Site (Province, Country)

4.5.2 China Based Manufacturers Remicade (Infliximab) Monoclonal Antibody Production Value (2018-2023)

4.5.3 China Based Manufacturers Remicade (Infliximab) Monoclonal Antibody Production (2018-2023)

4.6 Rest of World Based Remicade (Infliximab) Monoclonal Antibody Manufacturers and Market Share, 2018-2023

4.6.1 Rest of World Based Remicade (Infliximab) Monoclonal Antibody Manufacturers, Headquarters and Production Site (State, Country)

4.6.2 Rest of World Based Manufacturers Remicade (Infliximab) Monoclonal Antibody Production Value (2018-2023)

4.6.3 Rest of World Based Manufacturers Remicade (Infliximab) Monoclonal Antibody Production (2018-2023)

5 MARKET ANALYSIS BY TYPE

5.1 World Remicade (Infliximab) Monoclonal Antibody Market Size Overview by Type: 2018 VS 2022 VS 2029

5.2 Segment Introduction by Type

5.2.1 Brand

5.2.2 Biosimilar

5.3 Market Segment by Type

5.3.1 World Remicade (Infliximab) Monoclonal Antibody Production by Type (2018-2029)

5.3.2 World Remicade (Infliximab) Monoclonal Antibody Production Value by Type (2018-2029)

5.3.3 World Remicade (Infliximab) Monoclonal Antibody Average Price by Type (2018-2029)

6 MARKET ANALYSIS BY APPLICATION

6.1 World Remicade (Infliximab) Monoclonal Antibody Market Size Overview by Application: 2018 VS 2022 VS 2029

6.2 Segment Introduction by Application

6.2.1 Ankylosing Spondylitis

6.2.2 Rheumatoid Arthritis

6.2.3 Crohn's Disease

6.2.4 Other

6.3 Market Segment by Application

6.3.1 World Remicade (Infliximab) Monoclonal Antibody Production by Application (2018-2029)

6.3.2 World Remicade (Infliximab) Monoclonal Antibody Production Value by Application (2018-2029)

6.3.3 World Remicade (Infliximab) Monoclonal Antibody Average Price by Application (2018-2029)

7 COMPANY PROFILES

7.1 J & J

7.1.1 J & J Details

7.1.2 J & J Major Business

7.1.3 J & J Remicade (Infliximab) Monoclonal Antibody Product and Services

7.1.4 J & J Remicade (Infliximab) Monoclonal Antibody Production, Price, Value, Gross Margin and Market Share (2018-2023)

7.1.5 J & J Recent Developments/Updates

7.1.6 J & J Competitive Strengths & Weaknesses

7.2 Pfizer

7.2.1 Pfizer Details

7.2.2 Pfizer Major Business

7.2.3 Pfizer Remicade (Infliximab) Monoclonal Antibody Product and Services

7.2.4 Pfizer Remicade (Infliximab) Monoclonal Antibody Production, Price, Value, Gross Margin and Market Share (2018-2023)

7.2.5 Pfizer Recent Developments/Updates

7.2.6 Pfizer Competitive Strengths & Weaknesses

7.3 Organon

7.3.1 Organon Details

7.3.2 Organon Major Business

7.3.3 Organon Remicade (Infliximab) Monoclonal Antibody Product and Services

7.3.4 Organon Remicade (Infliximab) Monoclonal Antibody Production, Price, Value, Gross Margin and Market Share (2018-2023)

7.3.5 Organon Recent Developments/Updates

7.3.6 Organon Competitive Strengths & Weaknesses

7.4 Amgen

7.4.1 Amgen Details

7.4.2 Amgen Major Business

7.4.3 Amgen Remicade (Infliximab) Monoclonal Antibody Product and Services

7.4.4 Amgen Remicade (Infliximab) Monoclonal Antibody Production, Price, Value, Gross Margin and Market Share (2018-2023)

7.4.5 Amgen Recent Developments/Updates

7.4.6 Amgen Competitive Strengths & Weaknesses

8 INDUSTRY CHAIN ANALYSIS

8.1 Remicade (Infliximab) Monoclonal Antibody Industry Chain

8.2 Remicade (Infliximab) Monoclonal Antibody Upstream Analysis

8.2.1 Remicade (Infliximab) Monoclonal Antibody Core Raw Materials

8.2.2 Main Manufacturers of Remicade (Infliximab) Monoclonal Antibody Core Raw Materials

8.3 Midstream Analysis

8.4 Downstream Analysis

8.5 Remicade (Infliximab) Monoclonal Antibody Production Mode

8.6 Remicade (Infliximab) Monoclonal Antibody Procurement Model

8.7 Remicade (Infliximab) Monoclonal Antibody Industry Sales Model and Sales Channels

8.7.1 Remicade (Infliximab) Monoclonal Antibody Sales Model

8.7.2 Remicade (Infliximab) Monoclonal Antibody Typical Customers

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

10.1 Methodology

10.2 Research Process and Data Source

10.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Remicade (Infliximab) Monoclonal Antibody Production Value by Region (2018, 2022 and 2029) & (USD Million)

Table 2. World Remicade (Infliximab) Monoclonal Antibody Production Value by Region (2018-2023) & (USD Million)

Table 3. World Remicade (Infliximab) Monoclonal Antibody Production Value by Region (2024-2029) & (USD Million)

Table 4. World Remicade (Infliximab) Monoclonal Antibody Production Value Market Share by Region (2018-2023)

Table 5. World Remicade (Infliximab) Monoclonal Antibody Production Value Market Share by Region (2024-2029)

Table 6. World Remicade (Infliximab) Monoclonal Antibody Production by Region (2018-2023) & (K Units)

Table 7. World Remicade (Infliximab) Monoclonal Antibody Production by Region (2024-2029) & (K Units)

Table 8. World Remicade (Infliximab) Monoclonal Antibody Production Market Share by Region (2018-2023)

Table 9. World Remicade (Infliximab) Monoclonal Antibody Production Market Share by Region (2024-2029)

Table 10. World Remicade (Infliximab) Monoclonal Antibody Average Price by Region (2018-2023) & (US\$/Unit)

Table 11. World Remicade (Infliximab) Monoclonal Antibody Average Price by Region (2024-2029) & (US\$/Unit)

Table 12. Remicade (Infliximab) Monoclonal Antibody Major Market Trends

Table 13. World Remicade (Infliximab) Monoclonal Antibody Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)

Table 14. World Remicade (Infliximab) Monoclonal Antibody Consumption by Region (2018-2023) & (K Units)

Table 15. World Remicade (Infliximab) Monoclonal Antibody Consumption Forecast by Region (2024-2029) & (K Units)

Table 16. World Remicade (Infliximab) Monoclonal Antibody Production Value by Manufacturer (2018-2023) & (USD Million)

Table 17. Production Value Market Share of Key Remicade (Infliximab) Monoclonal Antibody Producers in 2022

Table 18. World Remicade (Infliximab) Monoclonal Antibody Production by Manufacturer (2018-2023) & (K Units)

Table 19. Production Market Share of Key Remicade (Infliximab) Monoclonal Antibody Producers in 2022

Table 20. World Remicade (Infliximab) Monoclonal Antibody Average Price by Manufacturer (2018-2023) & (US\$/Unit)

Table 21. Global Remicade (Infliximab) Monoclonal Antibody Company Evaluation Quadrant

Table 22. World Remicade (Infliximab) Monoclonal Antibody Industry Rank of Major Manufacturers, Based on Production Value in 2022

Table 23. Head Office and Remicade (Infliximab) Monoclonal Antibody Production Site of Key Manufacturer

Table 24. Remicade (Infliximab) Monoclonal Antibody Market: Company Product Type Footprint

Table 25. Remicade (Infliximab) Monoclonal Antibody Market: Company Product Application Footprint

Table 26. Remicade (Infliximab) Monoclonal Antibody Competitive Factors

Table 27. Remicade (Infliximab) Monoclonal Antibody New Entrant and Capacity Expansion Plans

Table 28. Remicade (Infliximab) Monoclonal Antibody Mergers & Acquisitions Activity

Table 29. United States VS China Remicade (Infliximab) Monoclonal Antibody Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 30. United States VS China Remicade (Infliximab) Monoclonal Antibody Production Comparison, (2018 & 2022 & 2029) & (K Units)

Table 31. United States VS China Remicade (Infliximab) Monoclonal Antibody Consumption Comparison, (2018 & 2022 & 2029) & (K Units)

Table 32. United States Based Remicade (Infliximab) Monoclonal Antibody Manufacturers, Headquarters and Production Site (States, Country)

Table 33. United States Based Manufacturers Remicade (Infliximab) Monoclonal Antibody Production Value, (2018-2023) & (USD Million)

Table 34. United States Based Manufacturers Remicade (Infliximab) Monoclonal Antibody Production Value Market Share (2018-2023)

Table 35. United States Based Manufacturers Remicade (Infliximab) Monoclonal Antibody Production (2018-2023) & (K Units)

Table 36. United States Based Manufacturers Remicade (Infliximab) Monoclonal Antibody Production Market Share (2018-2023)

Table 37. China Based Remicade (Infliximab) Monoclonal Antibody Manufacturers, Headquarters and Production Site (Province, Country)

Table 38. China Based Manufacturers Remicade (Infliximab) Monoclonal Antibody Production Value, (2018-2023) & (USD Million)

Table 39. China Based Manufacturers Remicade (Infliximab) Monoclonal Antibody

Production Value Market Share (2018-2023)

Table 40. China Based Manufacturers Remicade (Infliximab) Monoclonal Antibody Production (2018-2023) & (K Units)

Table 41. China Based Manufacturers Remicade (Infliximab) Monoclonal Antibody Production Market Share (2018-2023)

Table 42. Rest of World Based Remicade (Infliximab) Monoclonal Antibody Manufacturers, Headquarters and Production Site (States, Country)

Table 43. Rest of World Based Manufacturers Remicade (Infliximab) Monoclonal Antibody Production Value, (2018-2023) & (USD Million)

Table 44. Rest of World Based Manufacturers Remicade (Infliximab) Monoclonal Antibody Production Value Market Share (2018-2023)

Table 45. Rest of World Based Manufacturers Remicade (Infliximab) Monoclonal Antibody Production (2018-2023) & (K Units)

Table 46. Rest of World Based Manufacturers Remicade (Infliximab) Monoclonal Antibody Production Market Share (2018-2023)

Table 47. World Remicade (Infliximab) Monoclonal Antibody Production Value by Type, (USD Million), 2018 & 2022 & 2029

Table 48. World Remicade (Infliximab) Monoclonal Antibody Production by Type (2018-2023) & (K Units)

Table 49. World Remicade (Infliximab) Monoclonal Antibody Production by Type (2024-2029) & (K Units)

Table 50. World Remicade (Infliximab) Monoclonal Antibody Production Value by Type (2018-2023) & (USD Million)

Table 51. World Remicade (Infliximab) Monoclonal Antibody Production Value by Type (2024-2029) & (USD Million)

Table 52. World Remicade (Infliximab) Monoclonal Antibody Average Price by Type (2018-2023) & (US\$/Unit)

Table 53. World Remicade (Infliximab) Monoclonal Antibody Average Price by Type (2024-2029) & (US\$/Unit)

Table 54. World Remicade (Infliximab) Monoclonal Antibody Production Value by Application, (USD Million), 2018 & 2022 & 2029

Table 55. World Remicade (Infliximab) Monoclonal Antibody Production by Application (2018-2023) & (K Units)

Table 56. World Remicade (Infliximab) Monoclonal Antibody Production by Application (2024-2029) & (K Units)

Table 57. World Remicade (Infliximab) Monoclonal Antibody Production Value by Application (2018-2023) & (USD Million)

Table 58. World Remicade (Infliximab) Monoclonal Antibody Production Value by Application (2024-2029) & (USD Million)

Table 59. World Remicade (Infliximab) Monoclonal Antibody Average Price by Application (2018-2023) & (US\$/Unit)

Table 60. World Remicade (Infliximab) Monoclonal Antibody Average Price by Application (2024-2029) & (US\$/Unit)

Table 61. J & J Basic Information, Manufacturing Base and Competitors

Table 62. J & J Major Business

Table 63. J & J Remicade (Infliximab) Monoclonal Antibody Product and Services

Table 64. J & J Remicade (Infliximab) Monoclonal Antibody Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)

Table 65. J & J Recent Developments/Updates

Table 66. J & J Competitive Strengths & Weaknesses

Table 67. Pfizer Basic Information, Manufacturing Base and Competitors

Table 68. Pfizer Major Business

Table 69. Pfizer Remicade (Infliximab) Monoclonal Antibody Product and Services

Table 70. Pfizer Remicade (Infliximab) Monoclonal Antibody Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)

Table 71. Pfizer Recent Developments/Updates

Table 72. Pfizer Competitive Strengths & Weaknesses

Table 73. Organon Basic Information, Manufacturing Base and Competitors

Table 74. Organon Major Business

Table 75. Organon Remicade (Infliximab) Monoclonal Antibody Product and Services

Table 76. Organon Remicade (Infliximab) Monoclonal Antibody Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)

Table 77. Organon Recent Developments/Updates

Table 78. Amgen Basic Information, Manufacturing Base and Competitors

Table 79. Amgen Major Business

Table 80. Amgen Remicade (Infliximab) Monoclonal Antibody Product and Services

Table 81. Amgen Remicade (Infliximab) Monoclonal Antibody Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)

Table 82. Global Key Players of Remicade (Infliximab) Monoclonal Antibody Upstream (Raw Materials)

Table 83. Remicade (Infliximab) Monoclonal Antibody Typical Customers

Table 84. Remicade (Infliximab) Monoclonal Antibody Typical Distributors

List Of Figures

LIST OF FIGURES

Figure 1. Remicade (Infliximab) Monoclonal Antibody Picture

Figure 2. World Remicade (Infliximab) Monoclonal Antibody Production Value: 2018 & 2022 & 2029, (USD Million)

Figure 3. World Remicade (Infliximab) Monoclonal Antibody Production Value and Forecast (2018-2029) & (USD Million)

Figure 4. World Remicade (Infliximab) Monoclonal Antibody Production (2018-2029) & (K Units)

Figure 5. World Remicade (Infliximab) Monoclonal Antibody Average Price (2018-2029) & (US\$/Unit)

Figure 6. World Remicade (Infliximab) Monoclonal Antibody Production Value Market Share by Region (2018-2029)

Figure 7. World Remicade (Infliximab) Monoclonal Antibody Production Market Share by Region (2018-2029)

Figure 8. North America Remicade (Infliximab) Monoclonal Antibody Production (2018-2029) & (K Units)

Figure 9. Europe Remicade (Infliximab) Monoclonal Antibody Production (2018-2029) & (K Units)

Figure 10. China Remicade (Infliximab) Monoclonal Antibody Production (2018-2029) & (K Units)

Figure 11. Japan Remicade (Infliximab) Monoclonal Antibody Production (2018-2029) & (K Units)

Figure 12. Remicade (Infliximab) Monoclonal Antibody Market Drivers

Figure 13. Factors Affecting Demand

Figure 14. World Remicade (Infliximab) Monoclonal Antibody Consumption (2018-2029) & (K Units)

Figure 15. World Remicade (Infliximab) Monoclonal Antibody Consumption Market Share by Region (2018-2029)

Figure 16. United States Remicade (Infliximab) Monoclonal Antibody Consumption (2018-2029) & (K Units)

Figure 17. China Remicade (Infliximab) Monoclonal Antibody Consumption (2018-2029) & (K Units)

Figure 18. Europe Remicade (Infliximab) Monoclonal Antibody Consumption (2018-2029) & (K Units)

Figure 19. Japan Remicade (Infliximab) Monoclonal Antibody Consumption (2018-2029) & (K Units)

Figure 20. South Korea Remicade (Infliximab) Monoclonal Antibody Consumption (2018-2029) & (K Units)

Figure 21. ASEAN Remicade (Infliximab) Monoclonal Antibody Consumption (2018-2029) & (K Units)

Figure 22. India Remicade (Infliximab) Monoclonal Antibody Consumption (2018-2029) & (K Units)

Figure 23. Producer Shipments of Remicade (Infliximab) Monoclonal Antibody by Manufacturer Revenue (\$MM) and Market Share (%): 2022

Figure 24. Global Four-firm Concentration Ratios (CR4) for Remicade (Infliximab) Monoclonal Antibody Markets in 2022

Figure 25. Global Four-firm Concentration Ratios (CR8) for Remicade (Infliximab) Monoclonal Antibody Markets in 2022

Figure 26. United States VS China: Remicade (Infliximab) Monoclonal Antibody Production Value Market Share Comparison (2018 & 2022 & 2029)

Figure 27. United States VS China: Remicade (Infliximab) Monoclonal Antibody Production Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: Remicade (Infliximab) Monoclonal Antibody Consumption Market Share Comparison (2018 & 2022 & 2029)

Figure 29. United States Based Manufacturers Remicade (Infliximab) Monoclonal Antibody Production Market Share 2022

Figure 30. China Based Manufacturers Remicade (Infliximab) Monoclonal Antibody Production Market Share 2022

Figure 31. Rest of World Based Manufacturers Remicade (Infliximab) Monoclonal Antibody Production Market Share 2022

Figure 32. World Remicade (Infliximab) Monoclonal Antibody Production Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 33. World Remicade (Infliximab) Monoclonal Antibody Production Value Market Share by Type in 2022

Figure 34. Brand

Figure 35. Biosimilar

Figure 36. World Remicade (Infliximab) Monoclonal Antibody Production Market Share by Type (2018-2029)

Figure 37. World Remicade (Infliximab) Monoclonal Antibody Production Value Market Share by Type (2018-2029)

Figure 38. World Remicade (Infliximab) Monoclonal Antibody Average Price by Type (2018-2029) & (US\$/Unit)

Figure 39. World Remicade (Infliximab) Monoclonal Antibody Production Value by Application, (USD Million), 2018 & 2022 & 2029

Figure 40. World Remicade (Infliximab) Monoclonal Antibody Production Value Market

Share by Application in 2022

Figure 41. Ankylosing Spondylitis

Figure 42. Rheumatoid Arthritis

Figure 43. Crohn's Disease

Figure 44. Other

Figure 45. World Remicade (Infliximab) Monoclonal Antibody Production Market Share by Application (2018-2029)

Figure 46. World Remicade (Infliximab) Monoclonal Antibody Production Value Market Share by Application (2018-2029)

Figure 47. World Remicade (Infliximab) Monoclonal Antibody Average Price by Application (2018-2029) & (US\$/Unit)

Figure 48. Remicade (Infliximab) Monoclonal Antibody Industry Chain

Figure 49. Remicade (Infliximab) Monoclonal Antibody Procurement Model

Figure 50. Remicade (Infliximab) Monoclonal Antibody Sales Model

Figure 51. Remicade (Infliximab) Monoclonal Antibody Sales Channels, Direct Sales, and Distribution

Figure 52. Methodology

Figure 53. Research Process and Data Source

I would like to order

Product name: Global Remicade (Infliximab) Monoclonal Antibody Supply, Demand and Key Producers, 2023-2029

Product link: <https://marketpublishers.com/r/G17A07E3B292EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G17A07E3B292EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

